1. Büchner Th, Urbanitz D, Hiddemann W et al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589
2. Büchner T, Hiddemann W, Wendt F, Maschmeyer G, Kuse R, Löffler H (1987) Early intensification by double induction (DI) in adult AML: A multicenter study of the AML Cooperative Group. Blood 70 [Suppl 1]: 752 (abstr)
3. Büchner Th, Hiddemann W, Blasius S et al. (1989) Adult AML: The role of chemotherapy intensity and duration. Two studies of the AMLCG. In: Büchner Th, Schellong G, Hiddemann W, Ritter J (eds) Acute Leukemias II. Springer, Berlin Heidelberg New York, pp 261–266
4. Büchner Th, Hiddemann W, Koch P et al. (1988) The role of myelosuppressive maintenance, immunotherapy, induction dose reduction in higher age, and double induction in adult acute myeloid leukemia (AML). Four studies of the AML Cooperative Group. In: Kimura K et al. (eds) Cancer chemotherapy: Challenges for the future, vol. 3. Excerpta Medica, Tokyo, pp 119–128
5. Büchner T, Hiddemann W, Koenigsmann M, Zuehlsdorf M, Woermann B, Boeckmann A, Aguion-Freire E, Innig G, Maschmeyer G, Ludwig WD, Heinecke A (1989) Hematologic and therapeutic effects of recombinant human GM-CSF following chemotherapy (CT) in patients with acute leukemias at higher age or after relapse. Blood 72 [Suppl 1]: 1021 (abstr)